Onvansertib - TrovaGene

Drug Profile

Onvansertib - TrovaGene

Alternative Names: NMS-1286937; NMS-P937; PCM 075

Latest Information Update: 17 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nerviano Medical Sciences
  • Developer TrovaGene
  • Class Antineoplastics; Piperazines; Pyrazoles; Quinazolines; Small molecules
  • Mechanism of Action Polo-like kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer
  • Phase I/II Acute myeloid leukaemia
  • Phase I Solid tumours
  • Preclinical Breast cancer; Lung cancer; Non-Hodgkin's lymphoma

Most Recent Events

  • 15 Aug 2018 Onvansertib receives Orphan Drug status for Acute myeloid leukaemia in European Union
  • 03 Aug 2018 Onvansertib is still in phase I trials for Solid tumours (Late stage disease, Metastatic disease, Second-line therapy or greater) in USA (TrovaGene pipeline, August 2018)
  • 03 Aug 2018 Preclinical trials in Lung cancer and Breast cancer in USA (PO) (TrovaGene pipeline, August 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top